Clinical Core

临床核心

基本信息

  • 批准号:
    10746569
  • 负责人:
  • 金额:
    $ 30.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary Acute kidney injury (AKI) is a public health concern with direct impact on clinical and patient-centered outcomes, and healthcare resource utilization and policy. Recognizing the paucity of breakthrough discoveries in AKI and the growing burden of this condition, the UAB-UCSD O’Brien Clinical Core (Core A) is designed to reduce the barriers for investigators to conduct effective clinical and translational research by providing a robust infrastructure to promote collaborative projects across pre-clinical, clinical and industry researchers. Core A will provide multifaceted consultation through a customized Project Gateway, access to clinical databases, available biorepositories, and novel bioinformatics and computational technologies such as the U-BRITE and Nightingale collaborative digital workspaces in partnership with the Clinical and Translational Science Awards (CTSA) programs at both institutions for the harmonization and interrogation of big data with a focus on personalized medicine in AKI. Specifically, Core A will facilitate collaborative digital workspaces for electronic health record (EHR) data acquisition, transformation, validation, and interrogation. The overarching goal is to catalyze the translation of bench discoveries to applications that impact human AKI. The Specific Aims are structured as follows. In Aim 1, we will provide access to clinical data of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to curated clinical data from prior clinical studies hosted by Core A (Aim 1A) and provide access to new harmonized real-world data from the EHR to support epidemiological surveillance of AKI (e.g., AKI incidence, risk factors and outcomes) and novel clinical research, including but not limited to AKI risk-classification, sub-phenotyping, and simulated trials (Aim 1B). In Aim 2, we will provide access to biospecimens of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to biospecimens from prior studies hosted by Core A (Aim 2A). In Aim 2B we will provide a novel platform to link biospecimens of patients at risk for or with AKI with EHR data. Core A will have dynamic communications and collaborations with the Pre-Clinical Core, the Resource Development Core, and the O’Brien Kidney Consortium. In this U54 application, we will build upon our expertise and established successes demonstrated through our currently funded O’Brien Center P30 award. Given our commitment and expertise, we are confident that Core A will provide innovative resources to the growing research community interested in AKI-related research.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Javier A. Neyra其他文献

Fluid Management for Critically Ill Patients with Acute Kidney Injury Receiving Kidney Replacement Therapy
接受肾脏替代治疗的急性肾损伤危重患者的液体管理
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Lawrence Ledoux;R. Wald;M. Malbrain;F. Carrier;S. Bagshaw;R. Bellomo;N. Adhikari;M. Gallagher;S. Silver;J. Bouchard;Michael J. Connor Jr.;Edward G. Clark;J. Côté;Javier A. Neyra;A. Denault;W. Beaubien
  • 通讯作者:
    W. Beaubien
Nephrology Critical Care: A Darwinian Evolution.
肾脏病学重症监护:达尔文进化论。
  • DOI:
    10.1053/j.ackd.2021.06.007
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Javier A. Neyra;Michael Heung
  • 通讯作者:
    Michael Heung
A case of hypokalemic paralysis secondary to distal renal tubular acidosis as a presenting symptom in Sjogrens syndrome
  • DOI:
    10.4172/2161-0959.c1.025
  • 发表时间:
    2016-05
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Javier A. Neyra
  • 通讯作者:
    Javier A. Neyra
Plasma Metabolites Do Not Change Significantly After 48 Hours in Patients on CRRT
CRRT 患者 48 小时后血浆代谢物没有显着变化
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    13.6
  • 作者:
    Benjamin R. Griffin;Matthew Ray;Kristy Rolloff;John T. Brinton;Javier A. Neyra;J. P. Teixeira;Kirby Mayer;Katja M. Gist;Muhammad Aftab;Diana I. Jalal;Julie Haines;Sarah Faubel
  • 通讯作者:
    Sarah Faubel
Heterogeneity in Acute Kidney Injury Management in Critically Ill Patients: National Survey
危重病人急性肾损伤管理的异质性:全国调查
  • DOI:
    10.1016/j.nurpra.2023.104776
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Khaled Shawwa;K. Akuamoah;Carrie Griffiths;Connor Nevin;N. Scherrer;Paul McCarthy;Matthew A. Sparks;Kianoush B. Kashani;Javier A. Neyra;A. Sakhuja
  • 通讯作者:
    A. Sakhuja

Javier A. Neyra的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Javier A. Neyra', 18)}}的其他基金

Resource Development Core
资源开发核心
  • 批准号:
    10746571
  • 财政年份:
    2023
  • 资助金额:
    $ 30.51万
  • 项目类别:
The Southeastern Acute Kidney Injury (SEAK) Alliance for the COPE-AKI Consortium
COPE-AKI 联盟东南部急性肾损伤 (SEAK) 联盟
  • 批准号:
    10451665
  • 财政年份:
    2021
  • 资助金额:
    $ 30.51万
  • 项目类别:
The Southeastern Acute Kidney Injury (SEAK) Alliance for the COPE-AKI Consortium
COPE-AKI 联盟东南部急性肾损伤 (SEAK) 联盟
  • 批准号:
    10670068
  • 财政年份:
    2021
  • 资助金额:
    $ 30.51万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.51万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了